Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: Preliminary results from two phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B

Thompson, A.; Thompson, A.; Gane, E.; Gane, E.; Fung, S.; Fung, S.; Seto, W. K.; Seto, W. K.; Flaherty, J. F.; Flaherty, J. F.; Suri,; Suri,; Lin, L.; Lin, L.; Gaggar, A.; Gaggar, A.; Subramanian, G. M.; Subramanian, G. M.; Chuang, W. L.; Chuang, W. L.; Agarwal, K.; Agarwal, K.; Janssen, H. L.; Janssen, H. L.; Buti, M.; Buti, M.; Chan, H. L.; Chan, H. L.

Links

ORCID

Tools

Export citation

Search in Google Scholar

Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: Preliminary results from two phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B

Journal article published in 2017 by A. Thompson, A. Thompson, E. Gane, E. Gane, S. Fung, S. Fung, W. K. Seto, W. K. Seto, J. F. Flaherty, J. F. Flaherty, Suri, Suri, L. Lin, L. Lin, A. Gaggar and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload